Yes, exploiting DNA repair pathways has emerged as a therapeutic strategy in oncology. For example, inhibiting PARP in cancer cells deficient in HR leads to synthetic lethality, selectively killing tumor cells while sparing normal cells. Additionally, modulating repair pathways can enhance the efficacy of chemotherapy and radiotherapy, which rely on inducing DNA damage to kill cancer cells.
